ValuEngine lowered shares of Opiant Pharmaceuticals (NASDAQ:OPNT) from a hold rating to a sell rating in a research note published on Friday.
Separately, TheStreet upgraded shares of Opiant Pharmaceuticals from a c+ rating to a b rating in a research report on Monday, October 16th.
Opiant Pharmaceuticals (NASDAQ:OPNT) traded up $1.70 on Friday, reaching $24.95. 62,810 shares of the company’s stock were exchanged, compared to its average volume of 83,505. Opiant Pharmaceuticals has a one year low of $5.00 and a one year high of $51.90. The stock has a market capitalization of $48.08, a PE ratio of 59.40 and a beta of -2.33.
In other news, major shareholder Geoffrey Wolf sold 2,570 shares of Opiant Pharmaceuticals stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $30.40, for a total value of $78,128.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 63.82% of the stock is owned by company insiders.
About Opiant Pharmaceuticals
Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.